The treatment of adolescents and young adults with acute lymphoblastic leukemia (Q38096307)

28 August 2017

The treatment of adolescents and young adults with acute lymphoblastic leukemia. (English)

1 reference

28 August 2017

1 reference

Joshua Lukenbill

1

1 reference

PubMed ID

23559026

28 August 2017

Anjali S Advani

series ordinal

2

1 reference

28 August 2017

1 June 2013

1 reference

Current hematologic malignancy reports

28 August 2017

1 reference

28 August 2017

8

1 reference

28 August 2017

91-97

1 reference

28 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0159-0

28 August 2017

0 references

cites work

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Adult acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Acute lymphoblastic leukemia in adolescents and young adults in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Improved prognosis for older adolescents with acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0159-0

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

21 January 2018

1 reference

12 December 2020

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

1 reference

12 December 2020

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

12 December 2020

Expression of c-abl in Philadelphia-positive acute myelogenous leukemia

1 reference

12 December 2020

Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience

1 reference

12 December 2020

Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience

1 reference

12 December 2020

The treatment of adolescents and young adults with acute lymphoblastic leukemia

1 reference

12 December 2020

Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study

1 reference

12 December 2020

Immunologic classification of leukemia and lymphoma

1 reference

12 December 2020

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.

1 reference

12 December 2020

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

1 reference

12 December 2020

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

1 reference

12 December 2020

Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group

1 reference

12 December 2020

10.1007/S11899-013-0159-0

Identifiers

DOI

1 reference

PubMed ID

23559026

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23559026